Sino Biological, Inc.’s Post

If your research involves early cancer detection, protein & antibody therapeutics or senescence, be sure to pencil in these upcoming webinars in September! Featuring experts from UCLA, Skunkworx Bio and Mayo Clinic, these webinars will be insightful for a myriad of scientists. #antibodies #therapeutics #proteins #cancer #senescence #webinar #scicomm

Read this interview with Jiseon Kim, Senior Researcher at PROGEN, which discusses the development of a novel antibody-based drug for the treatment of cancer and autoimmune diseases. 💡🔬 What you will learn: 🟩 How a novel bispecific antibody-based drug using Neo Tri-ImmunoGlobulin (NTIG) technology was developed 🟩 How the team solves significant challenges in their research, such as measuring drug activity and binding affinity, by utilizing advanced tools like label-free biomolecular interaction analysis 🟩 How the team emphasizes the importance of laboratory tools like pipettes for precision in experiments   Explore in this SelectScience® interview how NTIG technology and advanced methods help to develop new drugs with significantly improved cure rates for patients with cancer and autoimmune diseases, ultimately leading to healthier lives. Access the interview now: https://ow.ly/mWgX50SCp4T #Sartorius #LiquidHandling #Pipetting #Pipette #Laboratory #LabEssentials #Antibody

The Smith Research Lab pioneers microwave-assisted Groebke-Blackburn-Bienayme’ synthesis of imidazoles, offering a rapid method to create compound libraries. Our focus lies in targeting key proteins linked to cancer resistance, providing novel insights for therapeutic advancements. 🌐 https://lnkd.in/eB-3H5UD #SmithResearchLab #MicrowaveSynthesis #GroebkeBlackburnBienayme #ImidazoleSynthesis #CompoundLibraries #CancerResearch #ProteinTargets #TherapeuticAdvancements #DrugDiscovery #ScientificInnovation #ChemistryLab #Biochemistry #ResearchDiscovery #BowieStateUniversity #NaturalSciences #STEMResearch #ScienceBreakthroughs #InnovativeMethods #ChemicalSynthesis #MedicalAdvancements

Accelerate Your Research with Matched Collections from CSD BIO Biobank! To support investigations focused on developing new drugs and liquid biopsy-based tests, we provide a wide spectrum of matched collections of tissues and blood product sets in various combinations: FFPE and plasma sets FFPE, Buffy coat, and plasma sets FFPE and PBMC sets These sets can also be combined with snap-frozen or fresh-frozen samples, slides, and sequencing data to facilitate multi-omics research. Matched samples ensure that tissue and blood products come from the same donor, providing a consistent biological context. This consistency is crucial for comparative studies, as it eliminates variability introduced by different donor sources. For example, in cancer research, having both tumor tissue (FFPE) and plasma from the same patient allows researchers to correlate tissue-specific mutations with circulating biomarkers, enhancing the reliability and relevance of study findings. Choose CSD BIO for high-quality, matched biospecimens to enhance the precision and impact of your research. For more information on our collections and how we can support your research goals, visit our website. 🔗 CSD BIO #Biobanking #PrecisionMedicine #Research #FFPE #matchedsamples #CSDbio #Biotechnology #Biobank #Biospecimens #CancerResearch #Pathology #ClinicalResearch #WSI #NSG

Having a sweet craving? 🍫 Cancer cells are also sweet-tooths who thrive on glucose, the simplest form of sugar. Heightened glucose consumption fuels these cells’ energetic demands, and supports the biosynthesis of essential macromolecules required for cell division and proliferation. However, we have gathered proof that by depriving cancer cells of glucose, we can efficiently target this metabolic weakness by blocking the GLUT1 transporter. Want to know how we do it? Luckily for you, our CSO Mart Ustav Jr. , Medical Director Anu Ustav, and Principal Scientist and lead researcher for the GLUT1 project Siret Tahk will be in #AACR, in San Diego, USA from April 5th - 10th. Presenting this same exact topic in more detail and are open to discussions. Catch them on Monday, April 8th from 9:00 AM - 12:30 PM (poster 1876) or connect via LinkedIn to set up a meeting during the entire conference. #biotechnology #oncology #biomarker

👏👏👏 WoW! Our customers published an article in Nature Biotechnology!   Due to the expansion of population-scale databases to millions of protein-coding variants, the understanding of their mechanistic consequences has lagged behind. 🤩   🔥 🔥 🔥 This article introduced PROD-ATAC, a high-throughput method for discovering the effects of protein-coding variants on chromatin regulation. A pooled variant library was expressed in a disease-agnostic cell line, and a single-cell transposase-accessible chromatin analysis was performed to resolve the impact of each variant on the chromatin landscape. Using PROD-ATAC, we analyzed over 100 oncofusions (cancer-causing chimeric proteins) and their controls, revealing that chromatin remodeling was common across a wide range of fusion frequencies. Furthermore, fusion-induced dysregulation may have been context-agnostic, as the observed mechanisms frequently overlapped with prior knowledge specific to cancer and cell types. This article also demonstrated that gain-of-function activity was prevalent among oncofusions.   ✨ This work begins to outlines a global map of fusion-induced chromatin alterations and suggests the possibility of convergent mechanisms among diverse oncofusions and shared modes of dysregulation present in tumors at different frequencies. PROD-ATAC is generalizable to any set of protein-coding variants.   https://lnkd.in/g5dGsbbS   For more push, please follow #Twitter: https://lnkd.in/gntQ9qE7   Related Product Recommendation:   #Entrectinib (NMS-E628; RXDX-101; https://lnkd.in/gw8hqPAJ);   #DMSO (Dimethyl sulfoxide; https://lnkd.in/ephUV2dZ);   #TritonX100 (https://lnkd.in/gKejxn5T);   #DMEM (DMEM (High Glucose, L-Glutamine, Pyruvate, Phenol Red, no HEPES); https://lnkd.in/gf9UaZ8F)   # NatureBiotechnology #PROD-ATA #Protein-coding #Cancer #MCE #MedChemExpress

Recently published 😊 This book highlights the recent advancement in point-of-care testing (POCT) technologies utilizing ‘smart’ nanomaterials for the analysis of biomarkers related to disease, which includes metabolites, enzymes, proteins, nucleic acids, cancer cells and multidrug-resistant pathogen. Further details can be obtained from: https://lnkd.in/gtdz3EVv #nanotechnology #nanomaterials #smart #application #biomedicalresearch #biomedicalengineering #nanoparticles

Research published in the peer-reviewed journal Nature demonstrated the ability of SNAP-CAR to provide a powerful adaptor strategy for fully programmable targeting of engineered cells to multiple antigens, including CD19. Based on these findings, Coeptis Therapeutics and the team at the University of Pittsburgh plan to expand the development of the SNAP-CAR platform to target the #autoimmune diseases in addition to #hematologic and solid tumors. Read the research here: https://lnkd.in/ggvUweaJ #Biotech #Science #CARTtherapy

🧬🔬 Dive into the world of biotech with our latest article on enzyme conjugation! Discover how linking enzymes to molecules can revolutionize therapeutic treatments, boosting stability and precision. From cancer therapy to innovative drug delivery systems, the future of personalized medicine is here! 👉 Read more and stay ahead in the biotech game: https://lnkd.in/ef_dqFq6 #EnzymeConjugation #Biotechnology #MedicalInnovation

This week we sequenced FBX23, short for F-Box Only Protein 23. FBX23 is involved in the regulation of protein degradation through the ubiquitin-proteasome pathway. Research has implicated FBX23 in various cellular processes, including cell cycle regulation, DNA repair, and apoptosis. Studies have shown that FBXO23 can target tumor suppressor proteins for degradation, promoting cancer progression. Our sequencing result demonstrates how Next-Generation Protein Sequencing™ data on the Platinum® instrument can be used to sequence and characterize potential therapeutic targets, such as mutations of FBX23. By analyzing the kinetic signatures from specific N-terminal amino acid recognizers, we identified 13 amino acids (F, Y, W, L, I, V, R, A, S, N, Q, E, and K), enabling identification of 5 peptides of FBX23 as shown in the figure. Discover the power of Platinum® and download our application notes here: https://lnkd.in/dsUSBvsh Which protein should be sequenced next? Let us know by commenting on this post or contact us here: #proteomics #QSI #proteinsequencing #NGPS #biotech